目录产品 » CD19[FITC], His, Human
Manual
SDS
COAs

CD19[FITC], His, Human

CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
￥9900
Z04145-100

产品简介
Species Human
Protein Construction
CD19 (Pro20-Lys291)
Accession # P15391-1		 His
N-term C-term
Conjugate FITC
Purity > 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 60.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
查看更多
返回

图例
CD19[FITC], His, Human

The purity of CD19[FITC], His, Human is greater than 95% as determined by SEC-HPLC. »

CD19[FITC], His, Human

CD19[FITC], His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

CD19[FITC], His, Human

Immobilized CD19[FITC], His, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD19 Antibody, hFc Tag with the EC50 of 9.3 ng/ml determined by ELISA. »

CD19[FITC], His, Human

FACS Analysis of Anti-CD19 CAR expression. 293T cells were transfected with anti-CD19-scFv and His tag. Cells were incubated with 10 μg/ml CD19[FITC], His, Human, His Tag and FITC-labeled protein control. Non-transfected 293T cells and FITC-labeled protein control were used as negative control. »

<
>

技术背景
Target Background CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
Synonyms CD19; B4; CVID3; Leu-12; MGC12802
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.